Risk and predictors of cardiovascular disease in psoriasis: a population-based study


  • Conflicts of interest: Funded in part by the National Institute on Aging (R01 AG034676 from the) and an unrestricted research grant from Amgen.

Hilal Maradit-Kremers, md, msc
Mayo Clinic, Department of Health Sciences Research
200 First St. SW
Rochester, MN 55905
E-mail: maradit@mayo.edu


Background  Emerging evidence suggests that severe psoriasis is associated with increased risk of cardiovascular disease. The goal of this study was to examine the risk and predictors of clinical cardiovascular events in psoriasis.

Methods  We performed a historical cohort and a nested case–cohort study using the population-based resources in Olmsted County, Minnesota. The study population included a population-based incidence cohort of patients with psoriasis first diagnosed between January 1, 1970, and January 1, 2000, and 2678 age- and sex-matched non-psoriasis subjects. Cardiovascular events, including hospitalized myocardial infarction, coronary revascularization procedures, stroke, heart failure, and cardiovascular death.

Results  Psoriasis was associated with an increased risk of myocardial infarction based on diagnostic codes (hazard ratio 1.26; 95% confidence intervals: 1.01, 1.58) but not when the analyses were restricted to validated myocardial infarction (hazard ratio 1.18; 95% confidence intervals: 0.80, 1.74). Psoriasis was not associated with an increased risk of heart failure or cardiovascular death. Traditional cardiovascular risk factors were significantly associated with cardiovascular risk in psoriasis. Each 1% increase in Framingham risk score at psoriasis incidence corresponded with a 5–10% increase in risk of cardiovascular events.

Conclusion  In this large incidence cohort of patients with psoriasis representing the full disease severity spectrum, psoriasis was not associated with an increased cardiovascular risk.